error
Die ETH-Bibliothek ist vom Mi., 24.12.2025 bis So., 04.01.2026 geschlossen. Während dieser Zeit können weiterhin neue Einträge in der Research Collection eingereicht werden. Ab Mo., 05.01.2026 sind wir gerne wieder für Sie da. // The ETH Library will be closed from Wednesday, December 24, 2025, to Sunday, January 4, 2026. During this time, new publications can still be submitted to the Research Collection. We will be happy to assist you again starting Monday, January 5, 2026.
 

Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis


METADATA ONLY
Loading...

Date

2006-02

Publication Type

Journal Article

ETH Bibliography

yes

Citations

Altmetric
METADATA ONLY

Data

Rights / License

Abstract

Vascular endothelial growth factor (VEGF) promotes angiogenesis, and elevated levels are found in plaques of psoriasis. Two VEGF polymorphisms, +405 and −460, are associated with early-onset psoriasis and are close to the functional activator protein-1 site (+419) through which retinoids, an established systemic therapy for psoriasis, can block production of VEGF. We report that peripheral blood mononuclear cells (PBMCs) and epidermal keratinocytes (KC) from patients with psoriasis demonstrate differential, genotype-dependent, regulation of VEGF. For PBMCs, VEGF genotype distinguishes two groups of patients with psoriasis – “high and low VEGF producers” (P<0.001). In contrast, KC production of VEGF is not genotype dependent. However, the effects of all-trans retinoic acid (RA) on cellular expression of VEGF are determined by both cell type and genotype. RA inhibits KC production of VEGF in a genotype-dependent manner (P<0.005) whereas RA stimulates PBMCs production irrespective of VEGF genotype (P<0.001). We also report that the −460 VEGF polymorphism appears to have a clinical pharmacogenetic role in predicting response or non-response of psoriasis to acitretin (P=0.01). In future, determination of VEGF gene polymorphisms and thus individual patient VEGF “signatures” may be used as a prognostic factor for psoriasis susceptibility/severity and as a means for optimizing treatment response.

Publication status

published

Editor

Book title

Volume

126 (2)

Pages / Article No.

453 - 459

Publisher

Nature

Event

Edition / version

Methods

Software

Geographic location

Date collected

Date created

Subject

Organisational unit

03683 - Detmar, Michael (emeritus) / Detmar, Michael (emeritus) check_circle

Notes

Funding

Related publications and datasets